Apixaban is used to lower the risk of stroke brought on by a blood clot in people with a heart rhythm disorder called atrial fibrillation. Apixaban is also used after hip or knee substitute surgical treatment to avoid a type of blood embolism called deep blood vessel thrombosis, which can lead to embolism in the lungs. This type of blood clot can occur during a spinal tap or back anesthetic, particularly if you have a hereditary spine issue, if you use a spinal catheter, if you've had spinal surgical treatment or duplicated spinal faucets, or if you use other drugs that can affect blood clotting. Your physician might prescribe another medicine to protect against blood embolisms if you stop taking apixaban for any reason. Its molecular formula is C25H25N5O4, which corresponds to a molecular weight of 459. 5 Apixaban has the complying with structural formula: Apixaban is a white to pale-yellow powder. At physical pH, apixaban does not ionize; its aqueous solubility across the physical pH range is ~ 0. 04 mg/mL. ELIQUIS tablets are offered for oral administration in strengths of 2. 5 mg and 5 mg of apixaban with the following inactive active ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose salt, salt lauryl sulfate, and magnesium stearate. The film finishing consists of lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide or red iron oxide. These blood clots can take a trip to the lungs and can end up being lodged in the capillary of the lungs, triggering a problem called pulmonary blood clot. This medication is used for numerous days after hip or knee substitute surgical procedure while you are unable to stroll. It is during this time that blood clots are most likely to form. Apixaban is also used to avoid stroke and embolism in patients with specific heart rhythm issue. Apixaban is a variable Xa inhibitor, an anticoagulant. This medicine is offered only with your doctor's prescription.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions
** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.
https://www.drugs.com/mtm/apixaban.html
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9481622-7cc6-418a-acb6-c5450daae...
https://www.mayoclinic.org/drugs-supplements/apixaban-oral-route/description/drg-20060729
CID | MolecularFormula | MolecularWeight | CanonicalSMILES | IsomericSMILES | InChI | InChIKey | IUPACName | XLogP | ExactMass | MonoisotopicMass | TPSA | Complexity | Charge | HBondDonorCount | HBondAcceptorCount | RotatableBondCount | HeavyAtomCount | IsotopeAtomCount | AtomStereoCount | DefinedAtomStereoCount | UndefinedAtomStereoCount | BondStereoCount | DefinedBondStereoCount | UndefinedBondStereoCount | CovalentUnitCount |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
10182969 | C25H25N5O4 | 459.5 | COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N | COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N | InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32) | QNZCBYKSOIHPEH-UHFFFAOYSA-N | 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide | 2.2 | 459.19065430 | 459.19065430 | 111 | 777 | 0 | 1 | 5 | 5 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Plex Page is a Biology & Health Sciences "Online Knowledge Base," where a machine summarizes all the summaries.
Contact
General contact: [email protected]